Low TIM3 expression indicates poor prognosis of metastatic prostate cancer and acts as an independent predictor of castration resistant status
Abstract T cell immunoglobulin 3 (TIM3) is a cell surface star molecule expressed on T cells, and also marks dysfunctional CD8+ T cells in various kinds of cancers. However, there are few studies focusing on the expression of TIM3 in tumor cells. In our study, we recruited 139 patients with metastat...
Guardado en:
Autores principales: | Junlong Wu, Guowen Lin, Yao Zhu, Hailiang Zhang, Guohai Shi, Yijun Shen, Yiping Zhu, Bo Dai, Dingwei Ye |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/39cac70173af47caa234244c5507cde9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients
por: Weijie Gu, et al.
Publicado: (2017) -
Cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
por: Nikolai A. Ognerubov
Publicado: (2021) -
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
por: Jingsong Zhang, et al.
Publicado: (2017) -
Advanced Therapeutic Options for Treatment of Metastatic Castration Resistant Prostatic Adenocarcinoma
por: Faiza Naseer, et al.
Publicado: (2021) -
Clinical characteristics and outcomes for patients with non‑metastatic castration-resistant prostate cancer
por: Peter Arnold, et al.
Publicado: (2021)